• Spyre Therapeutics priced an underwritten public offering of 4,117,648 common shares at USD 85.00 each.
• Gross proceeds expected at about USD 350 million; underwriters hold a 30-day option for up to about USD 52.5 million more.
• Closing targeted for Oct. 7, 2026, subject to customary conditions.
• Net proceeds earmarked to advance immunology pipeline programs, including late-stage development plans for SPY072 in hidradenitis suppurativa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610052013PRIMZONEFULLFEED9840149) on October 06, 2026, and is solely responsible for the information contained therein.